Charles River Laboratories International, Inc. (NYSE:CRL) CEO James C. Foster Acquires 6,075 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) CEO James C. Foster bought 6,075 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This represents a 3.42 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Charles River Laboratories International Trading Up 0.5 %

Shares of NYSE:CRL traded up $0.86 during midday trading on Friday, hitting $163.11. 1,215,947 shares of the stock traded hands, compared to its average volume of 1,060,465. The stock has a market capitalization of $8.34 billion, a PE ratio of 1,087.39, a P/E/G ratio of 6.77 and a beta of 1.37. The business’s 50 day moving average is $173.39 and its two-hundred day moving average is $188.81. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.46 earnings per share. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 9.41 earnings per share for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently modified their holdings of CRL. Wellington Management Group LLP raised its stake in shares of Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. D1 Capital Partners L.P. bought a new position in Charles River Laboratories International in the fourth quarter worth about $172,752,000. Norges Bank bought a new position in Charles River Laboratories International in the fourth quarter worth about $98,886,000. Nomura Holdings Inc. bought a new position in Charles River Laboratories International in the fourth quarter worth about $56,820,000. Finally, Raymond James Financial Inc. bought a new position in Charles River Laboratories International in the fourth quarter worth about $42,776,000. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research report on Monday, November 18th. JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday. Morgan Stanley cut their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Finally, UBS Group reiterated a “neutral” rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus target price of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).